2020 global pharmaceutical company CEO salary competition: Johnson & Johnson approaches 200 million GSK, and Novartis heads bottom

In the special year of 2020, the strongest workers in the medical field will be happy and sad.

Also affected by the new crown epidemic, there are many multinational MNC CEOs whose annual salary has risen again, and they can also enjoy special business machine benefits, while some corporate CEOs find it difficult to be happy.

For example, Johnson & Johnson's Alex Gorsky salary rose by 16.

AbbVie’s Gonzalez received a salary of $24 million, an increase of 11% year-on-year from 2019.

The female CEO of GSK, whose salary is not high among many CEOs, has been reduced to US$9.

Multinational MNC CEO 2020 salary

Although Johnson & Johnson's total revenue in 2020 is US$82.

Alex Gorsky's salary in 2020 is as high as 29.

All this is due to Johnson & Johnson's new crown vaccine obtained an emergency use authorization application from the FDA.

In 2020, Johnson & Johnson's pharmaceutical business field performed strongly, achieving 8% growth.

AbbVie Gonzalez: $24 million

The revenue of Richard Gonzalez 2020, who has been at the helm of AbbVie since 2013, has risen again.

Gonzalez received a salary of 24 million U.

Under the leadership of Gonzalez, AbbVie officially completed the acquisition of Allergan.

And in 2020, AbbVie launched two immunization drugs Skyrizi and Rinvoq, generating 2.

Lilly David Ricks: $23.

In 2020, David Ricks' salary reached 23.

Under the leadership of David Ricks, Eli Lilly's 2020 revenue performance is gratifying, exceeding expectations.
Data show that in 2020, Eli Lilly’s total revenue was US$24.
54 billion, an increase of 10% year-on-year, which was higher than Eli Lilly’s expectations of US$23.
7 billion to US$24.
2 billion at the beginning of the year.
In addition, Eli Lilly also disclosed China's sales revenue in its annual report for the first time, which was US$1.
117 billion (+19%), of which Sintilimab, which cooperates with Cinda, contributed US$309 million.

In 2020, Eli Lilly carried out a number of heavy investment cooperation, such as signing a protein degradation research cooperation and licensing agreement with Wanchun Pharmaceutical for US$790 million, and Precision BioSciences reached a US$2.
7 billion cooperation on gene editing technology; acquisition and development for US$1.
04 billion Prevail Therapeutics for gene therapy of neurodegenerative diseases related to lysosomal dysfunction.

For 2021, Eli Lilly has higher performance expectations, and plans to reach US$26.
5 billion to US$28 billion in revenue in 2021.

Pfizer Albert Bourla: $21 million

In 2020, Pfizer successfully developed and launched the first COVID-19 vaccine due to its cooperation with BioNTech to seize the opportunity in vaccines, creating sales of 154 million U.
S.
dollars.

Albert Bourla, who officially took the post of CEO of Pfizer on January 1, 2019, has a significant salary change in 2020.
In 2020, its total compensation will be 21.
03 million US dollars, including 1.
65 million US dollars salary, 5.
49 million US dollars in cash incentive compensation and long-term incentive awards of 14 million US dollars in the form of Pfizer options.
And its total salary in 2019 was $19.
7 million.

However, Pfizer's overall revenue seems to be far from satisfactory.
Pfizer dropped from No.
3 in the TOP20 last year to No.
8 this year due to the spin-off of its generic drug business.

In 2020, Pfizer’s total revenue was 41.
9 billion U.
S.
dollars.
If Puqiang’s performance is excluded, it will increase by 2% compared to last year.
Its Prevnar13 pneumonia vaccine, with sales of US$5.
85 billion in 2020, is Pfizer's highest-income product.

Pfizer expects sales in 2021 to be 61.
4 billion U.
S.
dollars, and COVID-19 vaccine sales in 2021 are expected to reach approximately 15 billion U.
S.
dollars.

BMS Giovanni Caforio: $20 million

Unlike GSK and Novartis’s CEO cuts during the epidemic, Giovanni Caforio, BMS’s CEO and Chairman of the Board of Directors, who did not pay special attention to the COVID-19 vaccine competition,’s total revenue rose by 7% in 2020.

Caforio’s revenue in 2020 is approximately US$20.
5 million, including US$1.
7 million in base salary, US$13.
5 million in stock awards, and US$5 million in incentive plan compensation and “other” compensation.
What is interesting is that the "other pay" he enjoys includes the use of business jets for personal purposes to protect his health.

2020 is the first full year since BMS acquired Xinji.
Due to the consolidation of performance, BMS 2020's total revenue for the whole year increased by 63% from US$26.
145 billion in 2019 to US$42.
518 billion.

BMS's best-selling product, Revlimid, an anti-cancer drug from Xinji, had sales of $12.
1 billion, an increase of 12% over the previous year.
In addition, BMS’s Eliquis sales of 9.
2 billion U.
S.
dollars, an increase of 16%, analysis believes that the main reason for the increase is that Eliquis can reduce the risk of stroke and heart attack in COVID-19 patients.

It is worth noting that the BMS revenue pillar O medicines experienced a decline in performance for the first time in 2020, which was US$7 billion, a drop of 3%.

Amgen Robert Bradway: $20 million

Despite the decline in Amgen's performance in 2019, Robert Bradway also raised his salary by $1 million.
In the past 2020, under the pressure of declining performance in 2019, Bradway faced the fierce generic drug competition while coping with the black swan incident of new crown pneumonia.
Bradway still led Amgen to achieve growth, and its return was 2013.
Ten thousand dollars in compensation.

This includes a salary of US$1.
65 million, stock and option awards of US$14.
4 million.
A cash award of 3.
5 million U.
S.
dollars, and his other remuneration totaling nearly 600,000 U.
S.
dollars (including personal use of company aircraft, financial planning services, etc.
).

Its income is more than twice the salary of GSK Emma Walmsley, but it is nearly $10 million less than Johnson & Johnson's Alex Gorsky.

The data shows that Bradway is leading Amgen to reinvigorate and focus on expanding markets outside the United States.
The most representative is that Amgen has begun to enjoy the dividend of China's pharmaceutical innovation.
In 2020, Amgen completed a capital increase of US$421 million in BeiGene, and its shareholding in BeiGene reached about 20%.
In 2020, Amgen achieved revenue of 25.
42 billion U.
S.
dollars, a year-on-year increase of 9%.

Gilead Daniel O'Day: $18.
99 million

Daniel O'Day, who has officially served as the chairman and chief executive officer of Gilead from March 1, 2019, is regarded as the most suitable leader to lead Gilead into the future.

Daniel O'Day has worked at Roche for 30 years.
He joined Roche Pharmaceuticals in 1987 and has held various positions in the United States.
In 2006, Daniel O'Day served as President of Roche Molecular Diagnostics in California, then returned to Roche headquarters to lead the Roche Diagnostics department, and was later appointed as CEO of Roche Pharmaceuticals.

Gilead has high hopes for this new leader, hoping that he can lead Gilead to reverse the decline in revenue for three consecutive years.
The main task of Daniel O'Day is to find new sources of growth, and improving Gilead’s position in the oncology field is an important direction chosen by it.

Gilead's salary for O'Day is also quite generous.
O'Day's salary in 2019 was US$29.
1 million, a 69% increase from the previous CEO John F.
Milligan's salary of US$26 million in the 2018 fiscal year.
However, it includes an award of 14.
2 million U.
S.
dollars to compensate for his departure from Roche; 5.
68 million U.
S.
dollars to be paid in cash; and another 8.
5 million U.
S.
dollars as an equity award.

O'Day compensation for 2020 is US$18.
99 million, which includes a salary of US$1.
7 million, as well as US$11.
5 million in stock and option awards, US$4.
7 million in cash awards and US$1 million in other compensation.

In 2020, Gilead, led by O'Day, will shine globally because of Remdesivir.
However, this did not alleviate O'Day's anxiety.
At the JP Morgan conference held in January this year, O'Day said that during his 10 months at Gilead, he mainly thought about 3 things every day:

① How long can Gilead’s core business (anti-virus business) last? How much revenue will it have in the next 10 years?

②What does Gilead hold today? What are Gilead’s internal and external expertise in accumulation and expertise?

③What is Gilead planning to buy? What is Gilead’s next-generation mergers and acquisitions?

O'Day proposed that in the next 10 years, Gilead is confident to become the "king" in the field of anti-AIDS, and Biktarvy will become the growth engine of Gilead in the next 10 years.

It is understood that the sales of Gilead’s anti-AIDS product Biktarvy reached US$7.
259 billion in 2020, setting a single-drug sales record for AIDS drugs.
In 2020, Gilead’s HIV drugs created nearly US$17 billion, an increase of 3% year-on-year.
Global sales of hepatitis C drugs continued to shrink, with sales of US$2.
064 billion.
The company's cell therapy revenue soared 33%, Yescarta and Tecartus contributed $607 million.

For the whole year of 2020, Gilead’s total revenue was 24.
689 billion U.
S.
dollars, a year-on-year increase of 10%.
However, unless the revenue of Redsey Veklury was 2.
811 billion U.
S.
dollars during the special period, Gilead’s total revenue fell by 3% compared with 2019.

Sanofi Paul Hudson: $13.
56 million

In September 2019, Paul Hudson joined Sanofi as CEO, and 2020 is also his first full salary year.
Although Sanofi’s full-year net income declined slightly in 2020, Sanofi’s board of directors still gave Paul Hudson a full affirmation.

In 2020, Paul Hudson received approximately US$13.
56 million in salary, including a basic salary of US$1.
55 million, an annual bonus of US$2.
64 million, other benefits of US$4.
82 million, and a signing bonus of US$2.
33 million.

Data show that Sanofi's net income in 2020 was 36.
04 billion euros, down 0.
2% year-on-year.
Among them, the pharmaceutical business revenue was 25.
674 billion euros (+3.
1%), the vaccine business revenue was 5.
973 billion euros (+8.
8%), and the consumer health care business revenue was 4.
394 billion euros (-1.
9%).
Its Dupixent (duplicumumab) revenue rose by 70% in 2020 and sold 3.
534 billion euros.

For Sanofi's performance in 2020, Paul Hudson also expressed satisfaction, believing that the company has overcome the severe challenges of the external environment and achieved the established operational and financial goals.

Moderna Stéphane Bancel: $13 million

As an online celebrity vaccine company, the annual salary of the CEO of Moderna in 2020 has exceeded the US$9.
7 million of the CEO of GSK and US$11.
61 million of the CEO of Novartis.

It is understood that the total salary of Moderna CEO Stéphane Bancel in 2020 is 12.
85 million U.
S.
dollars, higher than the 8.
9 million U.
S.
dollars in 2019.
This includes a salary of $950,000, a bonus of $1.
9 million and stock options worth $9 million.

2020 is a "historic year" for Moderna.
Thanks to the sales of the new crown vaccine, Moderna's revenue in the fourth quarter of 2020 reached 571 million U.
S.
dollars, while its revenue in the same period in 2019 was only 14 million U.
S.
dollars.
Moderna predicts that the sales of the new crown pneumonia vaccine in 2021 will reach 18.
4 billion US dollars.

Stéphane Bancel once said bluntly at the JPM conference: "With the success of the new crown vaccine research and development, Modena's image has been greatly improved, and it is expected to usher in the'turning point year' in 2021.
"

However, this vaccine company is very likely to be Wall Street's first short bid this year.
According to a survey of 80 hedge funds and professional investors by JPMorgan Chase, Moderna is one of the two biotech stocks most hopeful to short in 2021.
In 2020, Moderna stock rose by 434%.
According to data from S3 Partners, this increase caused Moderna's short position to lose $2.
14 billion.

GSK Emma Walmsley: $9.
7 million

So far, Emma Walmsley is still one of the few female CEOs of multinational MNCs.
Three years after being promoted to global CEO of GSK, Emma Walmsley finally got a salary increase in 2019.
In 2019, Emma Walmsley's package salary increased to 8.
4 million pounds, or about 10.
85 million U.
S.
dollars.

In 2020, although Emma Walmsley led GSK to reach its 2020 financial guidance target, its revenue was reduced to less than US$10 million, or approximately US$9.
7 million, because it did not achieve the company's internal profit target.

But in 2020, there is a huge gap between her income and the male CEOs of other companies.
For example, Alex Gorsky of Johnson & Johnson earned nearly 30 million U.
S.
dollars, and the total salary of Eli Lilly CEO David Ricks was 23.
7 million U.
S.
dollars.
AZ CEO Pascal Sorio received a salary of 21.
5 million US dollars.

The data shows that in 2020, GSK's annual revenue was 34.
099 billion pounds, an increase of 1% year-on-year.
The pharmaceutical business revenue was 17.
056 billion pounds and the vaccine business revenue was 6.
982 billion pounds, showing a slight decline of 3% and 2%.
As a result of the absorption of assets divested from Pfizer in the consumer healthcare business, revenue reached 10.
033 billion pounds, a year-on-year increase of 12%.

Original title: 2020 global pharmaceutical company CEO salary competition: Johnson & Johnson is close to 200 million yuan, GSK and Novartis are at the bottom, the difference is three times!